{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR&page=13", "query": { "condition": "EGFR", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 838, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T15:33:11.467Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06414733", "title": "HER-2 B Cell Peptide Vaccine", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "HER2-positive Breast Cancer", "EGFR Overexpression", "Metastatic Esophageal Carcinoma", "HER-2 Positive Esophageal Cancer" ], "interventions": [ { "name": "Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pravin T.P Kaumaya", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2025-01-17", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 1, "location_summary": "Indianpolis, Indiana", "locations": [ { "city": "Indianpolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414733" }, { "nct_id": "NCT04109066", "title": "Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel (PTX)", "type": "DRUG" }, { "name": "nivolumab placebo", "type": "OTHER" }, { "name": "anthracycline", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Endocrine Therapy", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 521, "start_date": "2019-11-18", "completion_date": "2023-12-27", "has_results": true, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 30, "location_summary": "Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Greenbrae", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04109066" }, { "nct_id": "NCT00754494", "title": "Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenomatous Polyp", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage I Colon Cancer", "Stage I Rectal Cancer", "Stage IIA Colon Cancer", "Stage IIA Rectal Cancer", "Stage IIB Colon Cancer", "Stage IIB Rectal Cancer", "Stage IIC Colon Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2008-07", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 3, "location_summary": "Long Beach, California • Orange, California • Chicago, Illinois", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00754494" }, { "nct_id": "NCT00404066", "title": "Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Albert Fisher", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 21, "start_date": "2006-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 2, "location_summary": "San Jose, California • Stanford, California", "locations": [ { "city": "San Jose", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00404066" }, { "nct_id": "NCT03992456", "title": "Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Colon Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8", "Unresectable Colon Adenocarcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Rectal Adenocarcinoma" ], "interventions": [ { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-04-24", "completion_date": "2024-10-07", "has_results": true, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03992456" }, { "nct_id": "NCT05597839", "title": "Study of DF9001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF9001", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-11-15", "completion_date": "2025-08-15", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 17, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05597839" }, { "nct_id": "NCT06186401", "title": "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EGFR Gene Mutation", "Glioblastoma", "MGMT-Unmethylated Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "E-SYNC T Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide (non-investigational)", "type": "DRUG" }, { "name": "Fludarabine (non-investigational)", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Surgical resection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Hideho Okada, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-04-30", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06186401" }, { "nct_id": "NCT01450696", "title": "A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Herceptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 296, "start_date": "2011-12", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-28", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 9, "location_summary": "La Jolla, California • Los Angeles, California • Whittier, California + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Goshen", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01450696" }, { "nct_id": "NCT06452277", "title": "A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Non-small Cell Lung Cancer, HER2 Mutation" ], "interventions": [ { "name": "Sevabertinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2024-08-28", "completion_date": "2029-06-27", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 25, "location_summary": "Newport Beach, California • San Diego, California • San Francisco, California + 20 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06452277" }, { "nct_id": "NCT00597597", "title": "Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2007-04", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2023-05-17", "last_synced_at": "2026-11-07T15:33:11.467Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00597597" } ] }